» Articles » PMID: 10807522

Unusual Patterns of Alloimmunity Evoked by Allogeneic Liver Parenchymal Cells

Overview
Journal Immunol Rev
Date 2000 May 12
PMID 10807522
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Despite the widely accepted view of the liver as an immunoprivileged tissue, purified allogeneic liver parenchymal cells delivered to the liver of a recipient mouse are highly antigenic. A functional transgenic model of hepatocyte transplantation in mice is used to explore host immune responses to allogeneic hepatocytes. Transplanted hepatocytes expressing human alpha-1-antitrypsin (hA1AT) are monitored for survival by the secretion of the transgene product hA1AT. Transplantation of transgenic hepatocytes into syngeneic or immunoincompetent severe combined immunodeficiency disease (SCID) mice results in indefinite hepatocellular allograft survival. However, transplantation of transgenic hepatocytes into allogeneic hosts results in rapid hepatocyte rejection. This rejection response is associated with prominent delayed type hypersensitivity responses to cellular alloantigen but minimal donor-reactive humoral immunity. Hepatocyte rejection is not controlled by host treatment with anti-CD4 mAb despite the ability of the same treatment regimen to produce indefinite survival of donor-matched heart allografts. Host immune responses to allogeneic hepatocytes utilize CD40L/CD40 but not CD28/B7 co-stimulation, unlike the activation of both of these systems in responses to other allografts. Furthermore, C57BL/6 mice which have been induced by anti-CD4 mAb or gallium nitrate treatment to accept heart allografts promptly reject donor-matched transgenic hepatocytes. Studies in reconstituted SCID, CD4 knockout (KO), and CD8 KO mice demonstrate that hepatocyte rejection can be initiated independently by either CD4+ T cells or CD8+ T cells, which again diverges from what has been observed for most other types of allografts. This may account for the relative resistance to immunoprotection for hepatocellular allografts with conventional immunosuppressive agents and to immunoregulatory states induced by other allografts. Three models of hepatocyte rejection are discussed.

Citing Articles

Germinal Center B Cells are Uniquely Targeted by Antibody-Suppressor CXCR5CD8 T Cells.

Zimmerer J, Chaudhari S, Koneru K, Han J, Abdel-Rasoul M, Uwase H Transplant Direct. 2025; 11(2):e1742.

PMID: 39802197 PMC: 11723704. DOI: 10.1097/TXD.0000000000001742.


Invariant NKT Cells Promote the Development of Highly Cytotoxic Multipotent CXCR3CCR4CD8 T Cells That Mediate Rapid Hepatocyte Allograft Rejection.

Zimmerer J, Ringwald B, Chaudhari S, Han J, Peterson C, Warren R J Immunol. 2021; 207(12):3107-3121.

PMID: 34810223 PMC: 9124232. DOI: 10.4049/jimmunol.2100334.


Hepatocyte Transplantation to the Liver via the Splenic Artery in a Juvenile Large Animal Model.

Siefert J, Hillebrandt K, Moosburner S, Podrabsky P, Geisel D, Denecke T Cell Transplant. 2019; 28(1_suppl):14S-24S.

PMID: 31842585 PMC: 7016464. DOI: 10.1177/0963689719885091.


Differential role of natural killer group 2D in recognition and cytotoxicity of hepatocyte-like cells derived from embryonic stem cells and induced pluripotent stem cells.

Cisneros T, Dillard D, Qu X, Arredondo-Guerrero J, Castro M, Schaffert S Am J Transplant. 2018; 19(6):1652-1662.

PMID: 30549427 PMC: 6543818. DOI: 10.1111/ajt.15217.


Cell-based liver therapies: past, present and future.

Iansante V, Chandrashekran A, Dhawan A Philos Trans R Soc Lond B Biol Sci. 2018; 373(1750).

PMID: 29786563 PMC: 5974451. DOI: 10.1098/rstb.2017.0229.